X2S1.F SINOPHARM GROUP 1/5/O.N.
- Market cap
- EUR 5.96B
- P/E
- 6.9x
- P/B
- 0.52x
- ROE
- 8.5%
- Dividend yield
- 4.46%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is X2S1.F undervalued?
Graham numberX2S1.F trades 60.0% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
SINOPHARM GROUP 1/5/O.N. fundamental analysis
No fundamental analysis for SINOPHARM GROUP 1/5/O.N. yet.
SINOPHARM GROUP 1/5/O.N. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About SINOPHARM GROUP 1/5/O.N.
Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and healthcare products, and medical devices in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices Distribution, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail pharmacy stores, and clinics. …
Full company profileSINOPHARM GROUP 1/5/O.N. financial statements
SINOPHARM GROUP 1/5/O.N. annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 521B | 552B | 597B | 585B | 575B |
| Gross Profit | 44.1B | 47.4B | 48.5B | 44.3B | 41.7B |
| Operating Income | 21.0B | 22.5B | 22.3B | 17.8B | 17.1B |
| EBITDA | - | 26.2B | 26.9B | 21.5B | 21.4B |
| Net Income | 7.76B | 8.53B | 9.05B | 7.05B | 7.16B |
| EPS | 2.49 | 2.73 | 2.90 | 2.26 | 2.29 |
| Balance Sheet | |||||
| Total Assets | 335B | 365B | 383B | 393B | 390B |
| Total Liabilities | 236B | 255B | 263B | 266B | 256B |
| Shareholders' Equity | 61.9B | 68.1B | 74.6B | 78.9B | 84.0B |
| Cash & Short-term Investments | 43.5B | 55.2B | 63.8B | 54.3B | 48.8B |
| Cash Flow | |||||
| Operating Cash Flow | 9.31B | 21.0B | 17.2B | 11.5B | 14.1B |
| Capital Expenditure | 2.26B | 2.42B | 2.34B | 1.97B | 1.62B |
| Free Cash Flow | 7.05B | 18.5B | 14.8B | 9.58B | 12.5B |
| Ratios | |||||
| ROE | 12.5% | 12.5% | 12.1% | 8.9% | 8.5% |
| ROA | 2.3% | 2.3% | 2.4% | 1.8% | 1.8% |
| Net Profit Margin | 1.5% | 1.5% | 1.5% | 1.2% | 1.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
SINOPHARM GROUP 1/5/O.N. dividends
- Dividend yield
- 4.46%
- Forward dividend
- 0.43 EUR
- Payout ratio
- 29.7%
- Ex-dividend date
- Jun 24, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 2.12B | 0.68 | 29.7% |
| 2024 | CNY 2.71B | 0.87 | 38.5% |
| 2023 | CNY 2.56B | 0.82 | 28.3% |
| 2022 | CNY 2.34B | 0.75 | 27.5% |
| 2021 | CNY 2.15B | 0.69 | 27.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns SINOPHARM GROUP 1/5/O.N.
- Insiders 0.00%
- Institutions 0.00%
- Public & others 100.00%
- Shares outstanding 268M
- Free float 255M
SINOPHARM GROUP 1/5/O.N. company profile
- Company name
- SINOPHARM GROUP 1/5/O.N.
- Ticker
- X2S1.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 94,910
- Fiscal year end
- December
- Address
- Sinopharm Group Building, Shanghai, China, 200023
- Phone
- 86 21 2305 2666
- Website
- sinopharmgroup.com.cn
About SINOPHARM GROUP 1/5/O.N.
Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and healthcare products, and medical devices in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices Distribution, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail pharmacy stores, and clinics. This segment also offers distribution, logistics, and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers, and other suppliers. The Medical Devices Distribution segment distributes medical devices, as well as provides installation and maintenance services. The Retail Pharmacy segment operates and franchises a network of retail drug stores. The Other Business segment engages in the distribution of laboratory supplies; manufacture and distribution of chemical reagents; and production and sale of pharmaceutical products. The company rents and manages properties; distributes medical instruments and equipment, Chinese herbal medicines, antibiotics, and biological products; and offers information technology, investment, goods and technology import and export, business consulting, health consultation, medical consulting, market information consulting and investigation, and convention and exhibition services. It also manages medical project investment, consulting, and technology training activities; and manufactures medicines. Sinopharm Group Co. Ltd. was founded in 2003 and is headquartered in Shanghai, the People's Republic of China. Sinopharm Group Co. Ltd. is a subsidiary of Sinopharm Industrial Investment Co., Ltd.
SINOPHARM GROUP 1/5/O.N. management
4- Mr. Wanyong LianPresident & Executive Director · born 1971
- Mr. Binghua YangExecutive Director · born 1980
- Ms. Xiaojuan LiChief Financial Officer · born 1976
- Mr. Yijian WuVP, Secretary to the Board & Company Secretary · born 1970